GSK has high hopes for Nucala thanks to its less frequent dosing – once a month, versus every other week for Dupixent – and ...

Investing.com -- China has approved GSK Plc ’s (LON:GSK) Nucala as an add-on maintenance treatment for adults with chronic ...

London-based drugmaker GSK has announced the UK approval of Nucala (mepolizumab) as an add-on maintenance biologic treatment ...

The approval is based on two placebo-controlled phase 3 studies, which showed mepolizumab significantly reduced the annualised rate of moderate/severe exacerbations and time to first moderate/severe ...

Welcome to Fierce Pharma's regulatory tracker for the first half of 2026. | In this tracker, Fierce Pharma is recording the ...

China NMPA approves GSK’s Nucala to treat adults with chronic obstructive pulmonary disease: London, UK Tuesday, January 6, 2026, 10:00 Hrs [IST] GSK plc announced that China’ ...

(Alliance News) - GSK PLC on Monday said mepolizumab, sold under the brand name Nucala, has been approved in China for use in adults with chronic obstructive pulmonary disease. The London-based ...

Pharma giant GSK has received regulatory approval in China for its Nucala treatment for adults with inadequately controlled ...

Throughout 2025, AbbVie’s Skyrizi and Johnson & Johnson’s Tremfya were mainstays at the top of the monthly TV drug ad ...

GSK (GSK) announced that China’s National Medical Products Administration, NMPA, has approved Nucala as add-on maintenance treatment of adult ...

(Alliance News) - Balfour Beatty sells ten UK assets for GBP87 million, Wizz Air and Ryanair report growth in passenger numbers for December, while Auction Technology Group rejects 11 takeover ...

OPEN The FTSE 100 was expected to open 57 points higher (+0.6%) ahead of the bell on Monday, after finishing Friday's session 0.2% higher at a record closing price of 9,951.14.